

# Attachment: COVID-19 Test & Diagnostic Reimbursement Strategy

## Appendix A: Procedure Codes

Procedure Codes	Description	Encounter Date Range	Cycle Priority
87635	INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]), AMPLIFIED PROBE TECHNIQUE	04/01/20 – 11/30/20	Cycle 1: STAR, STAR+PLUS, STAR Health, STAR+KIDS Cycle 2: CHIP
99001	HANDLING AND/OR CONVEYANCE OF SPECIMEN FOR TRANSFER FROM THE PATIENT IN OTHER THAN AN OFFICE TO A LABORATORY (DISTANCE MAY BE INDICATED)	04/01/20 – 11/30/20	Cycle 1: STAR, STAR+PLUS, STAR Health, STAR+KIDS Cycle 2: CHIP
C9803	HOSPITAL OUTPATIENT CLINIC VISIT SPECIMEN COLLECTION FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]), ANY SPECIMEN SOURCE	04/01/20 – 11/30/20	Cycle 1: STAR, STAR+PLUS, STAR Health, STAR+KIDS Cycle 2: CHIP
G2023	SPECIMEN COLLECTION FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]), ANY SPECIMEN SOURCE	04/01/20 – 11/30/20	Cycle 1: STAR, STAR+PLUS, STAR Health, STAR+KIDS Cycle 2: CHIP
G2024	SPECIMEN COLLECTION FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) FROM AN INDIVIDUAL IN A SNF OR BY A LABORATORY ON BEHALF OF A HHA, ANY SPECIMEN SOURCE	04/01/20 – 11/30/20	Cycle 1: STAR, STAR+PLUS, STAR Health, STAR+KIDS Cycle 2: CHIP
U0001	CDC 2019 NOVEL CORONAVIRUS (2019-NCOV) REAL-TIME RT-PCR DIAGNOSTIC PANEL	04/01/20 – 11/30/20	Cycle 1: STAR, STAR+PLUS, STAR Health, STAR+KIDS Cycle 2: CHIP
U0002	2019-NCOV CORONAVIRUS, SARS-COV-2/2019-NCOV (COVID-19), ANY TECHNIQUE, MULTIPLE TYPES OR SUBTYPES (INCLUDES ALL TARGETS), NON-CDC	04/01/20 – 11/30/20	Cycle 1: STAR, STAR+PLUS, STAR Health, STAR+KIDS Cycle 2: CHIP
U0003	INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]), AMPLIFIED PROBE TECHNIQUE, MAKING USE OF HIGH THROUGHPUT TECHNOLOGIES AS DESCRIBED BY CMS-2020-01-R	04/01/20 – 11/30/20	Cycle 1: STAR, STAR+PLUS, STAR Health, STAR+KIDS Cycle 2: CHIP
U0004	2019-NCOV CORONAVIRUS, SARS-COV-2/2019-NCOV (COVID-19), ANY TECHNIQUE, MULTIPLE TYPES OR SUBTYPES (INCLUDES ALL TARGETS), NON-CDC, MAKING USE OF HIGH THROUGHPUT TECHNOLOGIES AS DESCRIBED BY CMS-2020-01-R	04/01/20 – 11/30/20	Cycle 1: STAR, STAR+PLUS, STAR Health, STAR+KIDS Cycle 2: CHIP
86408	NEUTRALIZING ANTIBODY, SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]); SCREEN	As of the effective date 08/10/20 to 12/31/20	Cycle 3: STAR, STAR+PLUS, STAR Health, STAR+KIDS, CHIP
86409	NEUTRALIZING ANTIBODY, SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]); TITER	As of the effective date 08/10/20 to 12/31/20	Cycle 3: STAR, STAR+PLUS, STAR Health, STAR+KIDS, CHIP
86413	SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARSCOV-2) (CORONAVIRUS DISEASE [COVID-19]) ANTIBODY, QUANTITATIVE	As of the effective date 09/08/20 to 12/31/20	Cycle 3: STAR, STAR+PLUS, STAR Health, STAR+KIDS, CHIP
87636	INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SERVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS	As of the effective date 10/06/20 to 12/31/20	Cycle 3: STAR, STAR+PLUS, STAR Health, STAR+KIDS, CHIP

Procedure Codes	Description	Encounter Date Range	Cycle Priority
	DISEASE [COVID-19]) AND INFLUENZA VIRUS TYPES A AND B, MULTIPLEX AMPLIFIED PROBE TECHNIQUE		
87637	INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]), INFLUENZA VIRUS TYPES A AND B, AND RESPIRATORY SYNCYTIAL VIRUS, MULTIPLEX AMPLIFIED PROBE TECHNIQUE	As of the effective date 10/06/20 to 12/31/20	Cycle 3: STAR, STAR+PLUS, STAR Health, STAR+KIDS, CHIP
87811	INFECTIOUS AGENT ANTIGEN DETECTION BY IMMUNOASSAY WITH DIRECT OPTICAL (IE, VISUAL) OBSERVATION; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19])	As of the effective date 10/06/20 to 12/31/20	Cycle 3: STAR, STAR+PLUS, STAR Health, STAR+KIDS, CHIP
86328	IMMUNOASSAY FOR INFECTIOUS AGENT ANTIBODY(IES), QUALITATIVE OR SEMIQUANTITATIVE, SINGLE STEP METHOD (EG, REAGENT STRIP); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19])	04/01/20 – 12/31/20	Cycle 4: STAR, STAR+PLUS, STAR Health, STAR+KIDS, CHIP
86769	ANTIBODY; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19])	04/01/20 – 12/31/20	Cycle 4: STAR, STAR+PLUS, STAR Health, STAR+KIDS, CHIP
87426	INFECTIOUS AGENT ANTIGEN DETECTION BY IMMUNOASSAY TECHNIQUE, (E.G., ENZYME IMMUNOASSAY [EIA], ENZYME LINKED IMMUNOSORBENT ASSAY [ELISA], IMMUNOCHEMILUMINOMETRIC ASSAY [IMCA]) QUALITATIVE OR SEMIQUANTITATIVE, MULTIPLE-STEP METHOD; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (E.G., SARS-COV, SARSCOV-2 [COVID-19])	04/01/20 – 12/31/20	Cycle 4: STAR, STAR+PLUS, STAR Health, STAR+KIDS, CHIP
S8301	INFECTION CONTROL SUPPLIES, NOT OTHERWISE SPECIFIED	04/01/20 – 12/31/20	Cycle 4: STAR, STAR+PLUS, STAR Health, STAR+KIDS, CHIP